These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30444202)

  • 21. Glecaprevir/Pibrentasvir: First Global Approval.
    Lamb YN
    Drugs; 2017 Oct; 77(16):1797-1804. PubMed ID: 28929412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
    Gane E; Lawitz E; Pugatch D; Papatheodoridis G; Bräu N; Brown A; Pol S; Leroy V; Persico M; Moreno C; Colombo M; Yoshida EM; Nelson DR; Collins C; Lei Y; Kosloski M; Mensa FJ
    N Engl J Med; 2017 Oct; 377(15):1448-1455. PubMed ID: 29020583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study.
    Feld JJ; Cypel M; Kumar D; Dahari H; Pinto Ribeiro RV; Marks N; Kamkar N; Bahinskaya I; Onofrio FQ; Zahoor MA; Cerrochi O; Tinckam K; Kim SJ; Schiff J; Reichman TW; McDonald M; Alba C; Waddell TK; Sapisochin G; Selzner M; Keshavjee S; Janssen HLA; Hansen BE; Singer LG; Humar A
    Lancet Gastroenterol Hepatol; 2020 Jul; 5(7):649-657. PubMed ID: 32389183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.
    Gane E; Poordad F; Zadeikis N; Valdes J; Lin CW; Liu W; Asatryan A; Wang S; Stedman C; Greenbloom S; Nguyen T; Elkhashab M; Wörns MA; Tran A; Mulkay JP; Setze C; Yu Y; Pilot-Matias T; Porcalla A; Mensa FJ
    Clin Infect Dis; 2019 Oct; 69(10):1657-1664. PubMed ID: 30923816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens.
    Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2019 Jan; 91(1):102-106. PubMed ID: 30091810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.
    Forns X; Lee SS; Valdes J; Lens S; Ghalib R; Aguilar H; Felizarta F; Hassanein T; Hinrichsen H; Rincon D; Morillas R; Zeuzem S; Horsmans Y; Nelson DR; Yu Y; Krishnan P; Lin CW; Kort JJ; Mensa FJ
    Lancet Infect Dis; 2017 Oct; 17(10):1062-1068. PubMed ID: 28818546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects.
    Lin CW; Dutta S; Ding B; Wang T; Zadeikis N; Asatryan A; Kort J; Campbell A; Podsadecki T; Liu W
    J Clin Pharmacol; 2017 Dec; 57(12):1616-1624. PubMed ID: 28800195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1-6 infection: A systematic review and meta-analysis.
    Wang X; Fan X; Deng H; Zhang X; Zhang K; Li N; Han Q; Lv Y; Liu Z
    Int J Antimicrob Agents; 2019 Dec; 54(6):780-789. PubMed ID: 31284039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures.
    Osawa M; Imamura M; Teraoka Y; Uchida T; Morio K; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Chayama K;
    J Gastroenterol; 2019 Mar; 54(3):291-296. PubMed ID: 30334096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glecaprevir/pibrentasvir-associated acute liver injury in non-cirrhotic, chronic HCV infection without HBV co-infection.
    Hammami MB; Aboushaar R; Alsabbagh E
    BMJ Case Rep; 2019 May; 12(5):. PubMed ID: 31129632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers.
    Lin CW; Dutta S; Zhao W; Asatryan A; Campbell A; Liu W
    Eur J Drug Metab Pharmacokinet; 2018 Feb; 43(1):81-90. PubMed ID: 28688001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glecaprevir/Pibrentasvir and Renal Dysfunction in Deceased Donor Renal Transplantation: A Case Report.
    Kaba A; Yamanaga S; Hidaka Y; Toyoda M; Kashima M; Takekuma Y; Inadome A; Yokomizo H; Miyata A
    Transplant Proc; 2022 Mar; 54(2):549-551. PubMed ID: 35120765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials.
    Suleiman AA; Lin CW; Liu W; Eckert D; Mensing S; Burroughs M; Kato K; Chayama K; Kumada H; Oberoi RK
    J Clin Pharmacol; 2020 Mar; 60(3):331-339. PubMed ID: 31515816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection.
    Mensa FJ; Lovell S; Pilot-Matias T; Liu W
    Future Microbiol; 2019 Jan; 14():89-110. PubMed ID: 30499343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection.
    Toyoda H; Atsukawa M; Watanabe T; Nakamuta M; Uojima H; Nozaki A; Takaguchi K; Fujioka S; Iio E; Shima T; Akahane T; Fukunishi S; Asano T; Michitaka K; Tsuji K; Abe H; Mikami S; Okubo H; Okubo T; Shimada N; Ishikawa T; Moriya A; Tani J; Morishita A; Ogawa C; Tachi Y; Ikeda H; Yamashita N; Yasuda S; Chuma M; Tsutsui A; Hiraoka A; Ikegami T; Genda T; Tsubota A; Masaki T; Tanaka Y; Iwakiri K; Kumada T
    J Gastroenterol Hepatol; 2020 May; 35(5):855-861. PubMed ID: 31609495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects.
    Kosloski MP; Zhao W; Marbury TC; Preston RA; Collins MG; Pugatch D; Mensa F; Kort J; Liu W
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study.
    Aghemo A; Alberti A; Andreone P; Angelico M; Brunetto MR; Chessa L; Ciancio A; Craxì A; Gaeta GB; Galli M; Gasbarrini A; Giorgini A; Grilli E; Lampertico P; Lichtner M; Milella M; Morisco F; Persico M; Pirisi M; Puoti M; Raimondo G; Romano A; Russello M; Sangiovanni V; Schiavini M; Serviddio G; Villa E; Vinci M; De Michina A; Gallinaro V; Gualberti G; Roscini AS; Zignego AL;
    Dig Liver Dis; 2021 May; 53(5):612-619. PubMed ID: 32917546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C.
    Hsu SJ; Chiu MC; Fang YJ; Yang TH; Yu JJ; Chen CC; Kuo CC; Lee JY; Chen CH; Chen DS; Kao JH
    J Formos Med Assoc; 2019 Aug; 118(8):1187-1192. PubMed ID: 31279502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection in adults.
    Nehra V; Rizza SA; Temesgen Z
    Drugs Today (Barc); 2018 Jul; 54(7):407-421. PubMed ID: 30090878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy.
    Ohya K; Imamura M; Osawa M; Teraoka Y; Morio K; Fujino H; Ono A; Nakahara T; Murakami E; Yamauchi M; Kawaoka T; Hiramatsu A; Tsuge M; Aikata H; Hayes CN; Chayama K
    Clin J Gastroenterol; 2020 Apr; 13(2):267-270. PubMed ID: 31463795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.